

Medical Preferred Drug List (Medicaid) – July 2025

Prepared for Michigan

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
Alpha 1 Antitrypsin Deficiency	Aralast® (Alpha-1-Proteinase Inhibitor) Glassia® (Alpha-1-Proteinase Inhibitor) Zemaira® (Alpha-1-Proteinase Inhibitor)	Prolastin C® (Alpha-1-Proteinase Inhibitor)
Antiviral-MAB-RSV	Synagis® (palivizumab)	Beyfortus® (nirsevimab-alip)
Autoimmune – Infliximab/Remicade	Remicade (infliximab) Infliximab (unbranded) Renflexis (infliximab-abda)	Avsola (infliximab-axxq) Inflectra (infliximab-dyyb) Zymfentra (infliximab-dyyb)
Heme, IV Iron	Feraheme (ferumoxytol) Ferumoxytol (generic) Injectafer (ferric carboxymaltose) Monoferic (ferric derisomaltose)	Ferlecit (sodium ferric gluconate) Infed (Iron dextran) Venofer (iron sucrose)
Lysosomal Storage Disorders Gaucher Disease	VPRIV® (velaglycerase alfa) Elelyso® (taliglycerase alfa)	Cerezyme® (imiglycerase)
Multiple Sclerosis (Infused)	Lemtrada® (alemtuzumab) Briumvi (ublituximab-xiiy) Ocrevus Zunovo® (ocrelizumab-hyaluronidase) Tyruko (natalizumab)	Tysabri® (natalizumab) Ocrevus® (ocrelizumab)
Myasthenia Gravis/Paroxysmal Nocturnal Hemoglobinuria (PNH)	Soliris® (eculizumab)	Bkembv®(eculizumab-aeeb) Epysqli®(eculizumab-aagh)
Osteoarthritis, Viscosupplements	Gelsyn-3® (sodium hyaluronate) GenVisc® 850 (sodium hyaluronate) Hyalgan® (1% sodium hyaluronate) Hymovis (sodium hyaluronate) Orthovisc® (1% sodium hyaluronate) Supartz® FX (1% sodium hyaluronate) SynoJoynt® (1% sodium hyaluronate) Synvisc® (hylan (Avian) 8 mg/mL) Triluron® (sodium hyaluronate) TriVisc®(sodium hyaluronate) Visco-3® (1% sodium hyaluronate)	Euflexxa® (1% sodium hyaluronate)
*Oncology	Alymsys (bevacizumab-maly) **Avastin® (bevacizumab) Vegzelma (bevacizumab-adcd)	Mvasi™ (bevacizumab-awwb) Zirabev® (bevacizumab-bvzr)

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Drug Class	Non-Preferred Product(s)	Preferred Product(s)
	Herceptin® (trastuzumab) Herceptin Hycelta™ (trastuzumab and hyaluronidase-oysk) Hercessi (trastuzumab-strf) Herzuma® (trastuzumab-pkrb) Ogivri™ (trastuzumab-dkst) Ontruzant® (trastuzumab-dttb) Trazimera™ (trastuzumab-qyyp)	Kanjinti™ (trastuzumab-anns)
*Rituximab	Rituxan® (rituximab) Rituxan Hycela® (rituximab-hyaluronidase) Riabni™ (rituximab-arrx) Truxima® (rituximab-abbs)	Ruxience® (rituximab-pvvr)
Retinal Disorders (Eye)	Eylea® (aflibercept) Pavblu® (aflibercept) Enzeevu® (aflibercept) Ahzantive® (aflibercept) Opuviz® (aflibercept) Lucentis® (ranibizumab) Byooviz® (ranibizumab) Cimerli® (ranibizumab-eqrn) Beovu® (brolucizumab-dbl) Macugen (pegaptanib) Susvimo™ (ranibizumab) Vabysmo™ (faricimab-svoa) Visudyne® (verteporfin)	**Avastin® (bevacizumab)

*In specific states Evolent's preferred drug list will apply prior to Molina's. See [New Century Health's Website](#) for the Evolent ODL (oncology drug list). Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. **Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Molina Healthcare, Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

